Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10288488 | 0.91 | LMNA (0.32) | MAPTCDK8ACVR1NPBWR1LMNA | |
| SCHEMBL15063888 | 0.85 | KMT2A (0.32) | MAPTCDK8ACVR1LMNA | |
| SCHEMBL469902 | 0.84 | CRHR1 (0.34) | MAPTCDK8ACVR1LMNATP53 | |
| SCHEMBL509911 | 0.84 | — | — | |
| SCHEMBL15341167 | 0.78 | GRM5 (0.41) | NPBWR1TP53 | |
| SCHEMBL15086636 | 0.78 | CDK8 (0.36) | MAPTCDK8ACVR1LMNATP53 | |
| SCHEMBL469880 | 0.78 | HPGD (0.41) | CDK8ACVR1NPBWR1 | |
| SCHEMBL15341136 | 0.78 | NPBWR1 (0.31) | NPBWR1 | |
| SCHEMBL12481451 | 0.77 | — | — | |
| SCHEMBL510389 | 0.77 | MAPT (0.32) | MAPTCDK8ACVR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507410-B2 | Pyridazinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20120028803-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028803-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | C5, C1S, WEE1 | MAPT 4297/4885CDK8 1594/4885ACVR1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.